Summary High-dose etoposide (2.0-2.4 g m-2) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize perpheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity. Sixty-three patients with malignancy were enrolled into this non-randomized sequential study. The majority (55/63, 870,o) had received at least two prior regimens of chemotherapy. and seven patients had previously failed to mobilize following high-dose cyclophosphamide with G-CSF. Consecutive patient groups received etoposide at three dose levels [2.0 g m-2 (n = 22). 1.8 g m-2 (n = 20) and 1.6 g m-2 (n = 21)] followed by daily G-CSF. Subsequent leukaphereses were assayed for CD34-cell content, with a target total collection of 2.0 x 106 CD34-cells kg-'. Toxicity was assessed by the development of significant mucositis. the requirement for parenteral antibiotics or blood component support and rehospitalization incidence. Ten patients (169o) had less than the minimum target yield collected. Median collections in the three groups were 4.7 (2 g m-2). 5.7 (1.8 g m-2) and 6.5 (1.6 g m-2) x 106 CD34-cells kg-'. Five of the seven patients who had previously failed cyclophosphamide mobilization achieved more than the target yield. Rehospitalization incidence was significantly lower in patients receiving 1.6 g m-2 etoposide than in those receiving 2.0 g m-2 (P = 0.03). These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF. An etoposide dose of 1.6 g m-2 appears to be as effective as higher doses but less toxic.
(PBPC) support is increasinolv utilized in the treatment of patients x ith haematological or non-haematolo2ical malianant disease.
The mobilization of sufficient numbers of these progenitor cells from bone marrowx into the circulation for leukapheretic harvest mav be achieved by either a haemopoietic growth factor [at present usually granulocyte colony -stimulating-factor (G-CSF) or granulocv-te-macrophage colony -stimulating factor (GNI-CSF)] or cvtotoxic chemotherapy alone (Richman et al. 1976 : To et al. 1990 : Rosenfeld et al. 1996 : Diaz Mediavilla et al. 1996 How ex er. the combination of cytotoxic chemotherapy w-ith a 2row-th factor may be more effective (Gianni et al. 1989 : Schwartzberg et al. 1992 : Pettengell et al. 1993 .
Tu-o prexious reports has-e indicated that high-dose etoposide w-ith growxth factor may be employ ed for this purpose. Gianni et al (1992) studied an etoposide dose of 2.0-2.4 2 m-' Awith G-CSF or GNI-CSF. and in most patients minimal toxicity was experienced.
allo-Ming the regimen to be given as an outpatient procedure.
How-ever. none of these patients was heaxily pretreated. More recently. a study usingy etoposide at a dose of 2.0 g mr-x`ith G-CSF reported that nearly all patients. includingy those w ho had receix-ed more than two prior chemotherapy regimens. mobilized PBPCs successfully (Copelan et al. 1997) . A proportion of these latter patients dex eloped toxicity requiring hospitalization. W'e have exaluated w-hether reducing the dose of etoposide might lessen the toxicity experienced w-ithout significantly affecting the effectiveness of the mobilization procedure. The patient group studied was predominantly heavily pretreated and included some that had previously failed to mobilize adequately ,-ith hioh-dose cy clophosphamide and G-CSF
PATIENTS AND METHODS
Between September 1994 and September 1997. 63 patients with malignant disease w-ere enrolled into this non-randomized sequential studv. The first 22 patients received an etoposide dose of 2.0 m'. the next 20 patients a dose of 1.8 g m-' and the final 21 patients a dose of 1.6 g m-'. The total dose of undiluted etoposide X Mross et al. 1994) w as gix-en on day I as a continuous intravenous infusion via a central -ein over 10 h using a sxrin-e driver.
Patients w-ere hospitalized for the first 48 h of the mobilization procedure. All patients receixved prophylactic antiemetic therapy.
acetazolamide '250 mg, orally ex en-6 h for four doses) and methylprednisolone (40 mg m-' intravenouslI even-8 h for three doses) peri-infusion (Gianni et al. 1992 '. G-CSF 300 igc if body (Table 3) . Median yields (x lW CD-34 cells kE-w¼ in the three etoposide dosage groups sere 4.7 (2.0 m-n'. 5.7 (1.8 mr-) and (1998) 78(7). 928-932 6.5 (1.6 g m-) and the axerage number of leukaphereses required were 1.7(2.0Om-41.30.8gm-')and 1.50.6gm-4) . Fixe of the sexen patients w-ho had prev iously failed cyclophosphamide x-ith G-CSF mobilization achieved the target yield following etoposide/G-CSF (Table 4 ). The two patients in this group wxho did not mobilize successfully follow-ing etoposide/G-CSF had an underlyinc diagnosis of myeloma and both receixed 1.6 g m-etoposide.
DISCUSSION
Sexeral studies have suggested that the use of PBPCs to support high-dose therapy has advantages compared w ith autologous bone marrow (Elias et al. 1992 : Chao et al. 1993 : Schmitz et al. 1996 . These benefits mav include shorter median duration of neutropenia and thrombocv-topenia. fewxer febrile episodes with reduced antibiotic requirement. shorter hospitalization and lowxer procedural costs.
The procurement of PBPCs for this purpose has most often been accomplished using a combination of cvclophosphamide w-ith G-CSF. but not all patients mobilize successfully. In particular.
leukapheretic yields may be suboptimal in patients who have received sev eral preceding regimens of chemotherapy (Haas et al. 1994 : Dreger et al. 1995 . Strategies employed to improxe the results of mobilization hax e included increasing the dose of cyclophosphamide administered or using combinations of cytotoxic drugs (Lie et al. 1996 : Dernirer et al. 1997 : McQuaker et al. 1997 . The majoritx of patients (87%7c) in the present study had receixed at least two prior schedules of chemotherapy. and the mobilization therapy was successful in 53 of 63 patients (84%7c). In addition. fixve of sex en patients w-ho had prex iously failed to achieve a target collection of 2.0 x I0 CD34-cells kg-'I with cx clophosphamide/G-CSF mobilization x ielded an adequate harvest following etoposide/G-CSF. These data confirm that highdose etoposide with G-CSF is an effectix e mobilization regimen in the majority of patients. despite substantial prex ious therapy or an initial failure to mobilize PBPCs with cyclophosphamide/G-CSF.
The percentage of patients who mobilized PBPCs adequately and the median number of CD34-cells kg-1 obtained were not different between the three groups of etoposide dosage. In contrast. the toxicity experienced wvas lowest in those w ho received 1.6 g m-. with only 4 of these 21 patients needing readmission to hospital. In general. however. the toxic complications and rehospitalization frequency appear to haxe been greater than in the two previous reports of high-dose etoposide with G-CSF/GM-CSF. In the first study none of the patients ex aluated had been heaxily pretreated (Gianni et al. 1992) . and in the second approximatelv 50%7 of the patients studied had breast cancer (Copelan et al. 1997) . In a separate study at this centre PBPCs have been collected from more than 50 patients with high-risk primary breast cancer follox-ing mobilization with combination chemotherapy and G-CSF. and in none of these has readmission to hospital been required. suggesting that both prexious therapy and underlyinc diagnosis may impact on procedural complications.
The equixalent cell yields in the three groups of etoposide dosage may sugaest that a further reduction miaht eliminate toxicity w ithout impairinc PBPC mobilization. Howexer. although disease response x as not specifically exaluated in this study. there is evidence that high-dose etoposide is an effectixe agent in a varietv of tumours (Postmus et al. 1984 : Marangolo et al. 1989 : Herzig. 1991 : Bezwoda et al. 1992 . It may therefore be adxantageous to employ an etoposide dose sufficient to exploit this potential anti-tumour activitv. These data indicate that 1.6 m-' may represent a reasonable compromise for this purpose. enabling the successful mobilization of adequate PBPCs for the support of subsequent high-dose therapy but u ith acceptable toxicitx.
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